The effect of Tanacetum parthenium (L) Sch syrup on clinical manifestations of patients with COVID-19

Phase 3

Completed

• Conditions: Patients with Corona Virus.; Coronavirus infection, unspecified; B34.2

• Registration Number: IRCT20180610040049N4
• Lead Sponsor: Ghoum University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 18 May 2020

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Having informed consent to participate in the study
The definitive diagnosis of COVID-19
Failure to attend another clinical trial simultaneously

Exclusion Criteria

Patient's willingness to use other therapies
Alzheimer's patients

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
evel of CRP in serum. Timepoint: One day before the intervention and one day after the intervention is measured. Method of measurement: Using the ELISA technique.

Secondary Outcome Measures

Name	Time	Method
The rate of lung inflammation. Timepoint: One day before the intervention and one day after the intervention is measured. Method of measurement: CT SCAN.